Repositioning Candidate Details
| Candidate ID: | R0255 |
| Source ID: | DB00726 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Trimipramine |
| Synonyms: | 10,11-dihydro-N,N,β-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 5-(γ-dimethylamino-β-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; beta-Methylimipramine; Trimeprimine; Trimeproprimine; β-methylimipramine |
| Molecular Formula: | C20H26N2 |
| SMILES: | CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12 |
| Structure: |
|
| DrugBank Description: | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. |
| CAS Number: | 739-71-9 |
| Molecular Weight: | 294.4338 |
| DrugBank Indication: | For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance |
| DrugBank Pharmacology: | Trimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic. |
| DrugBank MoA: | Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT). |
| Targets: | Sodium-dependent serotonin transporter inhibitor; Sodium-dependent noradrenaline transporter inhibitor; Sodium-dependent dopamine transporter inhibitor; 5-hydroxytryptamine receptor 2A agonist; 5-hydroxytryptamine receptor 1A antagonist; Alpha-1A adrenergic receptor antagonist; Alpha-1B adrenergic receptor antagonist; Dopamine D2 receptor other/unknown; Alpha-2B adrenergic receptor other/unknown; Histamine H1 receptor antagonist; 5-hydroxytryptamine receptor 2C antagonist; 5-hydroxytryptamine receptor 3A binder; 5-hydroxytryptamine receptor 1D binder; Alpha-2A adrenergic receptor antagonist; D(1) dopamine receptor binder; Beta adrenergic receptor binder; Muscarinic acetylcholine receptor binder; 5-hydroxytryptamine receptor 1C binder |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|